NHS saves 1.2 billion pounds on medicines over three years

1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...

Read more →

Looking back, UK patients unhappy with adalimumab biosimilar switch

24 June 2020 - The UK results show how challenging switching to a biosimilar can be, according to patient groups. ...

Read more →

Achieving cost savings with biosimilars will require new strategies, authors say

20 January 2020 - Improving access to fairly priced, quality-assured generics and biosimilars is essential to realizing the potential public ...

Read more →

Is it time to look beyond price with biosimilars?

5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...

Read more →

Biosimilars in the UK: where are we now and where does the NHS want to go?

9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the ...

Read more →

With Brexit looming, what does the future hold for UK biosimilars?

26 September 2019 - If and when the United Kingdom leaves the European Union, the Medicines and Healthcare Products Regulatory Agency ...

Read more →

Majority of patients not asked for consent before being switched to a biosimilar, survey finds

17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...

Read more →

NHS publishes update on the use of biosimilars

5 June 2019 - The United Kingdom’s National Health Service (NHS) has published a new document for clinical and nonclinical ...

Read more →

HTA frameworks for RA therapies need improvement, researchers say

13 May 2019 - Cost-effectiveness models for the treatment of rheumatoid arthritis first emerged in the early 2000s when highly effective ...

Read more →

NHS saves record £300 million by switching to cheaper arthritis drug

26 November 2018 - The NHS is set to save a record £300 million after negotiating deals with five manufacturers ...

Read more →

Biosimilar drugs promise to slash health care costs in rich countries

8 November 2018 - The world's top-selling drug now faces biosimilars that are 80% cheaper. ...

Read more →

Biosimilar adalimumab: a landmark for NHS medicines optimisation

23 October 2018 - The NHS’s bid to improve patient outcomes and save money by switching costly biological drugs for ...

Read more →

With payers under pressure, biosimilars must demonstrate their value

27 September 2018 - In recent years, payers in Europe have been increasing their scrutiny of new therapies as increasingly high-cost ...

Read more →

UK lags behind most of Europe in access to biologics for patients with rheumatoid arthritis

4 September 2018 - Global leader in biosimilars, Celltrion Healthcare announces support for the easing of initiation boundaries for biologics that ...

Read more →

Biosimilars for insulin: a cost-saving alternative?

11 August 2018 - The expiry of patents on an insulin analogue has opened the market to the production of biosimilar ...

Read more →